Homburger with Elanco International on incremental term facility
Homburger advised Elanco in Switzerland on any aspect of Swiss law within the transaction.
The background
On the 13th of August 2024, Elanco Animal Health and Elanco US entered into an incremental assumption agreement to obtain an incremental term facility. The granting of the comprehensive security package involving various jurisdictions was completed on September 9, 2024.
Elanco
Elanco Animal Health is an American pharmaceutical company specializing in medicines and vaccinations for pets and agricultural livestock. Previously a subsidiary of Eli Lilly, it became an independent entity after being divested in 2019.
The Homburger team
It was led by Daniel Haeberli (pictured) and included Simone Gloor and Julia Koch (all Financing) as well as Stefan Oesterhelt (Tax).
